Human medicines European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 Vaccine (ChAdOx1-S [recombinant]), COVID-19 virus infection, Date of authorisation: 29/01/2021, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 Vaccine (ChAdOx1-S [recombinant]), COVID-19 virus infection, Date of authorisation: 29/01/2021, Revision: 30, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), Online, 15:00 - 17:00 Amsterdam time (CEST), from 22/09/2023 to 22/09/2023

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), Online, 15:00 - 17:00 Amsterdam time (CEST), from 22/09/2023 to 22/09/2023

Human medicines European public assessment report (EPAR): Ristaben, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Ristaben, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 09/02/2018, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 09/02/2018, Revision: 20, Status: Authorised

Shaping a European innovation ecosystem: EU-Innovation network multi-stakeholder meeting, Hybrid (Madrid and online), from 26/09/2023 to 26/09/2023

Shaping a European innovation ecosystem: EU-Innovation network multi-stakeholder meeting, Hybrid (Madrid and online), from 26/09/2023 to 26/09/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness